Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
DALLAS and FORT WORTH, Texas, Aug. 31, 2016 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that Vipin Garg, PhD, President and CEO, will present at the Wells Fargo Securities 2016 Healthcare Conference on Thursday, September 8, 2016 at 9:55 a.m. ET in Boston, MA. Dr. Garg will provide a corporate update and discuss the Company’s key milestones and events, including the launch of Adzenys XR-ODT™, the first and only extended-release, orally disintegrating tablet for the treatment of ADHD and the Company’s first branded product commercially available in the United States.
A live webcast of the presentation will be available on the investor section of the company’s website, http://investors.neostx.com/. The webcast will be archived on the website following the presentation.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platforms. Adzenys XR-ODT is the first approved product using the Company’s XR-ODT technology platform. Neos, which is initially focusing on the treatment of ADHD, has two other branded product candidates that are XR medications in ODT or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®1, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
1Tussionex® is a registered trademark of the UCB Group of Companies.
CONTACT: Richard I. Eisenstadt, Chief Financial Officer Neos Therapeutics (972) 408‐1389 [email protected]
